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A r t i c l e s
We report a missense variant of the EGLN1 gene, c.12C>G, that is in almost complete linkage disequilibrium (LD) with a previously reported missense variant in this gene, c.380G>C. Both c.12C>G and c.380G>C are observed almost exclusively on a haplotype we previously identified as a strong candidate for conferring Tibetan high-altitude adaptation on the basis of tests of extended haplotype homozygosity (iHS and XPEHH) and association with protection from polycythemia 4 . Kinetic studies of recombinant p.[Asp4Glu; Cys127Ser] PHD2 and functional assessment of native erythroid progenitors homozygous for the variant encoding p.[Asp4Glu; Cys127Ser] PHD2 demonstrate that the variant protein has increased hydroxylase activity under hypoxic conditions. We demonstrate that this variant contributes to the molecular and cellular basis of Tibetan adaptation to high altitude by blunting the erythropoietic response to hypoxia.
RESULTS

Genomic screening for adaptive mutations in Tibetans
We first screened for sequence variants in candidate genes. Twentysix Tibetans living in Virginia and Utah (designated hereafter as US Tibetans) were recruited for our studies. The ancestral composition of the local Tibetans is depicted in Table 1 , and that of 121 Asian (Chinese, Japanese, Korean, Mongolian and Filipino) and European control subjects is shown in Supplementary Table 1. In earlier studies, variant alleles of EGLN1 (NCBI RefSeq NG_015865), EPAS1 (NCBI RefSeq NG_016000) and PPARA (NCBI RefSeq NG_012204) were significantly associated with lower hemoglobin concentrations in Tibetan highlanders [4] [5] [6] . Genomic DNA sequencing of the exons, exon-intron boundaries and promoter region of PPARA 15 did not identify any sequence variants in four Tibetans. No sequence variants in EPAS1 were identified in the 16 exons and exon-intron boundaries of genomic DNA from 2 Tibetans with the EPAS1 haplotype previously reported to be under positive selection. Initially, exon sequencing of EGLN1 in Tibetan genomic DNA identified 2 missense mutations in cis in exon 1: 22 genomic DNA samples had a new c.12C>G variant (NM_022051), and all 26 samples (at the time of the original evaluation) 7 had a known but unvalidated SNP, rs12097901 (c.380G>C; NM_022051). The minor allele frequency for the c.380G>C variant was reported to be 20% in the 1000 Genomes Project Phase 1 sample in 2011.
Frequency of the EGLN1 variants
We then determined the frequency of the c.12C>G and c.380G>C EGLN1 alleles in Tibetans and non-Tibetans ( Table 1 and Supplementary Table  1 ). The c.380G>C variant was found in all 26 US Tibetan DNA samples and occurred in non-Tibetan controls at a frequency of ~20%, which is consistent with the 1000 Genomes Project estimate. By comparison, the frequency of the c.12C>G variant was 85% in local Tibetans (20 homozygotes, 2 heterozygotes and 4 wild type) but only 0.8% in 242 non-Tibetans (occurring in 1 Mongolian subject and 1 Japanese subject, both of whom were heterozygous). This variant was submitted to the NCBI dbSNP database as ss538786686/rs186996510. More recently, we studied an additional 26 Tibetans living in Himachal Pradesh in northern India. We also collaborated with the Research Center for High-Altitude Medicine of Qinghai University in China, and the following subjects living on the QinghaiTibetan Plateau agreed to participate in our studies: 13 subjects from the provincial capital of Xining and 26 subjects from Huashixia township (Zorgenrawa in Tibetan), Madoi county in Qinghai province. In subjects from these expanded Tibetan cohorts (n = 65) and US Tibetans (n = 26), the frequency of the c.12C>G variant was 88% (n = 91; 46 homozygotes, 34 heterozygotes and 11 wild type; Supplementary Tables 2 and 3) . With the exception of one apparent intragenic crossover (Supplementary Table  2 , subject MG08), the c.12C>G allele was always observed on a haplotype containing the c.380G>C allele. Although we are not able to determine the level of population structure and/or admixture in each Tibetan cohort examined, we suspect that these factors underlie the differences observed between local and other Tibetans with respect to the frequency of c.12C>G homozygosity. Our recent analyses of regional Tibetan populations identify clustering of geographically separate groups within Tibet in addition to distinct differences in the amount of genetic admixture 16 .
Positive selection of the EGLN1 variants
To search for genomic evidence of positive selection for the c.[12C>G; 380G>C] compound allele of EGLN1, we genotyped >900,000 SNPs in 17 US Tibetan samples using the Genome-Wide Human SNP Array 6.0 (Affymetrix). We identified two pairs of Tibetans as close relatives (TU02 and TU04; TU05 and TU08) and excluded one of the related individuals from each pair from all subsequent analyses (Online Methods). Principalcomponents and ADMIXTURE analyses indicated that the ancestries of the current Tibetan samples were similar to those of the Tibetan population in which the selection signal at the EGLN1 locus was identified (Supplementary Fig. 1 ). Next, we estimated the population branch statistic (PBS), which compares pairwise estimates of population differentiation (F ST ) among three populations to detect sites that are highly divergent in the population of interest 6 . When comparing Europeans, Mongolians and Tibetans, the PBS for the c.12C>G variant of EGLN1 was 1.02, which was the fifth most extreme value that we observed (empirical P value = 9 × 10 −6 ) (Fig. 1) . The four SNPs with more extreme PBS values (rs12063614, rs12563076, rs11122250 and rs6541261) were also located at the EGLN1 locus ( Fig. 1) but did not cause amino acid changes in PHD2. Using population-based phasing on 16 US Tibetans, we estimated that the major allele for each of these 4 SNPs was present on 25 of the 26 chromosome copies (of a total of 32) that carried the c.12C>G variant. Thus, the elevated PBS 
Age of the EGLN1 variant
On the basis of high-density SNP data from 16 unrelated US Tibetans, we estimated the age of the c.12C>G mutation in EGLN1 by measuring the decay of LD surrounding the mutation using a previously described approach 17 . The maximum-likelihood estimate for the age of the c.12C>G mutation was 8,000 years, on the basis of a 25-year generation time (95% confidence interval (CI) = 5,100-11,900 years; Supplementary Table 4) . Because the c.380G>C allele was present at intermediate frequency in several non-Tibetan populations, the more recent c.12C>G mutation probably arose on a chromosome that contained the c.380G>C mutation. The relatively young estimated age and high frequency of this Tibetan-specific variant are consistent with a rapid increase in allele frequency due to strong positive natural selection. Fig. 2 ). The K m and V max values for DLD19, a 19-residue synthetic peptide encompassing the HIF-1α C-terminal hydroxylation site, were identical in all mutants to the values for the wild-type enzyme ( Table 2 ). The K m value was also assessed for a more natural substrate, the HIF-2α O 2 -dependent degradation domain (ODDD), a 250-amino-acid recombinant polypeptide encompassing both the Nand C-terminal prolyl hydroxylation sites of HIF-2α. For p.[Asp4Glu; Cys127Ser] PHD2, the K m was 100 nM, which is slightly higher than the 70 nM seen for wild-type PHD2 (P < 0.05; Table 2 ). However, the V max of p.[Asp4Glu; Cys127Ser] PHD2 for the HIF-2α ODDD was 30% greater than that for wild-type PHD2 (P < 0.005; Table 2 ), most likely reflecting compensation for a possible minor difference in hydroxylation due to the slightly higher K m value of the mutant. Next, we performed kinetic analyses of the two other cosubstrates of PHD2, 2-oxoglutarate (α-ketoglutarate) and oxygen 18 . The K m and V max values of p.[Asp4Glu; Cys127Ser] PHD2 for 2-oxoglutarate were determined using DLD19 as a substrate and were identical to those for the wild-type enzyme ( Table 2 ). The K m and V max values of the p.Asp4Glu and p.Cys127Ser PHD2 single mutants for O 2 were determined using the HIF-2α ODDD as a substrate and were identical to those of the wild-type enzyme ( Table 2) . However, the K m value of p.[Asp4Glu; Cys127Ser] PHD2 for O 2 was 110 µM, which is ~30% lower than the value of 150 µM for wild-type PHD2 (P < 0.05; Fig. 2a and Table 2 ), whereas the V max value was identical to that for the wild-type enzyme ( Table 2 ). The K m values of the p.Asp4Glu and p.Cys127Ser single mutants for O 2 were also significantly higher than that for the p.[Asp4Glu; Cys127Ser] double mutant (P = 0.05 and P < 0.05, respectively; Table 2 ), suggesting an epistatic interaction between the two mutations. Thus, the p.[Asp4Glu; Cys127Ser] protein is capable of more efficiently hydroxylating HIF α subunits at lower oxygen tensions than wild-type PHD2.
Kinetic analyses and in cellulo experiments
We then asked whether the lower K m of the p.[Asp4Glu; Cys127Ser] variant for oxygen resulted in alterations in HIF-2α stabilization. Hep3B hepatoma cells were infected with a lentivirus expressing a Venus fluorescent protein as a negative control, wild-type PHD2 or the PHD2 p.[Asp4Glu; Cys127Ser] variant. To directly compare wild-type PHD2 and the p.[Asp4Glu; Cys127Ser] mutant, endogenous PHD2 was knocked down using a short hairpin RNA (shRNA) targeting the 3′ UTR of EGLN1, which was lacking in the cDNAs used to express exogenous PHD2. After antibiotic selection for stably transduced cells, we cultured the cells in 21% or 1% O 2 for 12 h and quantified HIF-2α levels by protein blotting. Cells expressing the p.[Asp4Glu; Cys127Ser] variant had decreased HIF-2α protein levels under hypoxic conditions when compared to cells expressing wild-type PHD2 (Fig. 2b) . A similar trend was noted for HIF-1α, but the effect was less consistent. Knockdown of endogenous EGLN1 and equal transgene expression were confirmed to rule out differences due to dissimilar PHD2 expression levels (Fig. 2c) . These data suggest that Enzyme (Fig. 3a) . Hypersensitivity to EPO is a feature found in inherited disorders associated with increased HIF activity 3, 19 . Indeed, HIF-regulated gene expression was increased in normoxic cultures of erythroid colonies from Tibetans homozygous for the variant encoding p.[Asp4Glu; Cys127Ser] (Supplementary Fig. 3 ). However, analysis of erythropoiesis at ambient oxygen concentration does not reflect physiological hypoxia in the bone marrow, which is further accentuated by hypoxia at high altitudes. Thus, erythropoiesis was then reevaluated in vitro in a controlled hypoxic environment. Normal erythroid progenitors had exaggerated growth, increased hemoglobinization and increased sensitivity to EPO when incubated under hypoxic conditions (1% or 5% O 2 ; Fig. 3b-d) , as previously reported 20, 21 . However, concomitantly tested erythroid progenitors from six Tibetans (five subjects homozygous for the variant encoding p.[Asp4Glu; Cys127Ser] and one subject heterozygous for the variant encoding p.Asp4Glu; cells homozygous for the variant encoding p.Cys127Ser did not grow at all at 1% O 2 (Fig. 4) and, at 5% O 2 , their proliferation and hypersensitivity to EPO were decreased (Fig. 3b,c) . Additionally, the mean size of the BFU-Es from controls increased under hypoxic conditions, whereas the mean size (P = 0.0017) and hemoglobinization of the BFU-Es from homozygotes for the variant encoding p.[Asp4Glu; Cys127Ser] were decreased (Figs. 3d and 4) .
DISCUSSION
We report a new missense mutation in EGLN1, c.12C>G, that coexists in cis in c.[12C>G; 380G>C] with the previously reported c.380G>C EGLN1 variant and is present in the majority of Tibetans (SNP ss538786686/rs186996510) 7 . The c.12C>G mutation originated ~8,000 years ago, most likely on a haplotype with the c.380G>C mutation. The c.12C>G variant was not reported in an analysis of 50 Tibetan exomes 6 , likely owing to the high GC content in this region. Similarly, this region of exon 1 of EGLN1 could not be successfully sequenced in 54 high-coverage whole genomes from the Complete Genomics Diversity Panel 22 . Therefore, this region appears to have particularly poor coverage in next-generation sequence data, which explains why the c.12C>G variant escaped detection in previous studies.
The association of SNPs at the EGLN1 locus with high-altitude adaptation (absence of polycythemia) was reported previously in Tibetans 4 , as well as in Andeans 23 , and loss-of-function EGLN1 mutations are associated with dominantly inherited congenital polycythemia [24] [25] [26] [27] [28] . Furthermore, two SNPs in the first intron of EGLN1, rs479200 and rs480902, differ substantially in frequency between samples from highland and lowland populations in India and are associated with increased risk of high-altitude pulmonary edema in the latter 29 .
The catalytic domain of PHD2 starts at residue 181 and extends through the end of the 426-residue polypeptide. Several missense mutations affecting the catalytic domain and mutations that lead to a truncated protein lacking the catalytic domain have been reported previously to be linked to familial polycythemia [22] [23] [24] [25] [26] [27] [28] . The highaltitude Tibetan variant c.[12C>G; 380G>C] in EGLN1 enhances the catalytic activity of PHD2 under hypoxic conditions; however, it does not affect the catalytic domain. The currently available threedimensional structure of PHD2 only contains the catalytic domain; therefore, modeling of the p.Asp4Glu and p.Cys127Ser alterations is not feasible. However, our data suggest that the Tibetan c.[12C>G; 380G>C] variant alters oxygen binding and perhaps also HIF-2α substrate binding to PHD2 and, under hypoxia, is a gain-of-function mutation of PHD2, the principal negative regulator of HIFs.
When we demonstrated that the EGLN1 haplotype in Tibetans is associated with protection from polycythemia 4 , we hypothesized that this haplotype might be associated with an EGLN1 gain-of-function mutation resulting in decreased HIF activity and, possibly, decreased EPO levels and blunted erythropoiesis. However, our initial functional assessment of erythroid progenitors bearing the homozygous haplotype found that, under normoxia, it is associated with augmented rather than decreased erythropoiesis (Fig. 3a) . This feature is found in inherited disorders associated with increased HIF levels, as first reported for Chuvash polycythemia, which is caused by a missense mutation in VHL encoding a p.Arg200Trp alteration that reduces binding to hydroxylated HIF α subunits and thus increases HIF-1 and HIF-2 levels 30 npg sensitivity, colony size and hemoglobinization when incubated at 5% O 2 and did not grow at all at 1% O 2 . In striking contrast, control erythroid progenitors had exaggerated growth and increased EPO sensitivity, colony size and hemoglobinization under hypoxic conditions (1% or 5% O 2 ; Figs. 3a-d and 4) , as previously reported 20, 21 . Tibetan high-altitude adaptation is not determined by a single gene but by multiple evolved genetic adaptations acting in concert 33 . These mutations may have different effects on the regulation of erythropoiesis, as well as on metabolism, which is another major target of HIF regulation 34 . In aggregate, the data we present here support the key role of the c.[12C>G; 380G>C] variant in EGLN1 as a major molecular mechanism by which Tibetans are protected from developing polycythemia at high altitude. Further studies are warranted to determine whether these alleles also alter other pathological responses to high-altitude hypoxia, such as pulmonary hypertension. A more complete understanding of the genetic basis for adaptation to high altitude may lead to new approaches for the treatment of common causes of mortality, such as ischemic cardiovascular disease, in which hypoxia has a major pathophysiological role.
URLs. 1000 Genome Phase I: http://www.ncbi.nlm.nih.gov/projects/ SNP/snp_ref.cgi?rs=12097901.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Subjects. Twenty-six Tibetans residing in Virginia and Utah (referred to as US Tibetans) were recruited for the study. Institutional review board approval was obtained from the University of Utah Regulatory Knowledge and Clinical Research Ethics Committee in the United States, from the Sher-i-Kashmir Institute of Medical Science Ethics Committee in India and from the Quinghai University Institutional Ethics Committee in China; informed consent was obtained from all participants. Of the 26 US Tibetans, 11 originate in U-Tsang, 8 originated in Khamba, 1 originated in Amdo and 6 were of mixed Tibetan ancestry; none of the 26 subjects had any known chronic illness or history of smoking. DNA from healthy Salt Lake City volunteers was complemented by anonymous DNA from the Sorensen Molecular Genealogy Foundation (SMGF) and the Baylor College of Medicine Department of Genetics (BCMDG) population database, serving as controls. These controls constituted DNA from 74 European Americans, 14 subjects of mixed Asian ancestry (Korean, Japanese and Filipino) from Salt Lake City, 11 anonymous Mongolians 4,35 , 6 Japanese and 16 Han Chinese (SMGF and BCMDG). Additional information on subject recruitment is given in the Supplementary Note. Sample preparation. Peripheral blood was collected using acid citrate buffer (ACD) tubes, and plasma, mononuclear cells, granulocytes and platelets were separated and archived for future use with the Histopaque density gradient method (Sigma-Aldrich). Nucleic acids were extracted from granulocytes and mononuclear cells using TRI Reagent (Molecular Research Center), and, for some samples only, genomic DNA was isolated using the PureGene DNA purification kit (Qiagen). Mononuclear cells from subjects were used for evaluation of the sensitivity of erythroid progenitors to EPO (BFU-E assays; see below), and five BFU-E colonies were pooled from each individual separately and used for RNA isolation.
Genomic analyses. In general, for the initial screening of the PPARA and EGLN1 genes, four representative samples were used and two representative samples were used for EPAS1. The sequences for the promoter region of the PPARA gene 15 and the exons and intron-exon boundaries of the PPARA, EPAS1 and EGLN1 genes were obtained from NCBI GenBank via the NCBI website; the corresponding sequences were amplified using the primers and conditions listed in Supplementary Table 5 and were sequenced in both directions. PCR was carried out using Phusion High-Fidelity Master Mix (New England Biolabs) according to the manufacturer's recommended protocol.
Analysis of EGLN1 exon 1. Exon 1 of EGLN1 spans 4,047 bp, and the distal 891-nt region encodes the N terminus of the PHD2 protein. This region of exon 1 is GC rich (70%) with multiple repeats, and amplification was performed using forward primers flanking the coding region of exon 1 (Supplementary Table 5 ) with PreMix G from the FailSafe PCR System (Epicentre). The 1,025-bp amplicon generated by PCR was then purified using the QIAquick Gel Extraction kit (Qiagen) and sequenced in both directions. SNP genotyping. We genotyped 16 local Tibetans using the Affymetrix 6.0 SNP array (>900,000 SNPs) and performed genotype calling using the Affymetrix Genotyping Console 3.1 (Affymetrix). The genotypes used for analyses included all autosomes (no sex chromosomes or mitochondrial DNA). We augmented these samples with the HapMap CHB and JPT (Chinese and Japanese) populations (International HapMap Consortium, 2007) and with 31 Tibetan individuals and 25 Buryat Mongolian individuals who we previously genotyped 4, 35 . The sample of 25 Mongolian individuals included the 11 individuals genotyped for the c.12C>G and c.380G>C variants in EGLN1. We performed principal-components and AMIXTURE analyses ( Supplementary  Fig. 1 ) as previously described 36 , excluding related individuals. Using the tool Estimation of Recent Shared Ancestry (ERSA) 37 , we determined that 2 of the 18 local Tibetans were close relatives and excluded 1 of the related individuals from all subsequent analyses. We calculated PBS in the 16 local Tibetans and 11 Mongolians and 14 Europeans for c.12C>G and c.380G>C in EGLN1 and for all Affymetrix SNPs with a call rate of at least 95% in each sample. We used the Beagle software package 38 to estimate phase in the 16 local Tibetans. We then estimated the age of the c.12C>G mutation from the decay of LD in the local Tibetans, according to the methods described 17, 39 .
Reverse-transcription and real-time PCR. A portion (1 µg) of RNA was treated with DNase I to eliminate genomic DNA contamination. The integrity of the RNA was verified by agarose gel electrophoresis and by an optical density at 260/280 nm of 2.0 ± 0.2 as measure by NanoDrop 2000 (Thermo Fisher Scientific). RNA was then reverse transcribed using SuperScript VILO (Life Technologies) according to the manufacturer's instructions. Hydrolysis probes were acquired from Applied Biosystems (Life Technologies) and are listed in Supplementary Table 5 . The amount of each target mRNA was normalized using HPRT1 and GAPDH mRNA for granulocytes, whereas RPLP0 and TFRC mRNA were used for normalization of the erythroid progenitor colonies, on the basis of the eight reference genes used to validate normalization for blood and erythroid progenitors in using geNorm Plus (Biogazelle) (data not shown). Amplification reactions were carried out using the 7500 Real-Time PCR System (Applied Biosystems, Life Technologies) with 45 cycles of 95 °C for 15 s followed by 60 °C for 1 min. To assess reaction specificity, analyses were also carried out without reverse transcriptase or template, with both serving as negative controls.
Quantitative RT-PCR data and statistical analysis. The Livak method with REST 2009 software (Qiagen) was employed to analyze the generated data set using at least two reference genes. The data presented represent the mean and s.d. of at least two separate experiments performed in duplicate. Differences between control and Tibetan samples were analyzed using the Student's t test, and a P value of less than 0.05 was considered statistically significant.
Expression, purification and kinetic analyses of p.Asp4Glu, p.Cys127Ser and p.[Asp4Glu;Cys127Ser] PHD2. The mutations encoding p.Asp4Glu and p.Cys127Ser were introduced into human EGLN1 cDNA in a baculovirus vector 40 with a sequence encoding a C-terminal Flag-His tag using the primer pairs listed in Supplementary Table 5 and the QuikChange sitedirected mutagenesis kit (Stratagene). The resulting recombinant vectors were sequenced for the correct mutations. The vectors were cotransfected into Spodoptera frugiperda (Sf9) cells (Invitrogen) with BaculoGold DNA (Pharmingen) by calcium phosphate transfection, and the recombinant baculoviruses generated were amplified. Mutant and wild-type PHD2 proteins were expressed in H5 insect cells (Invitrogen) cultured in suspension in Sf900IISFM serum-free medium (Invitrogen) and were purified to near homogeneity with anti-Flag M2 affinity material, as described 40 . Kinetic analyses of the PHD2 mutants in comparison to wild-type enzyme were performed by an assay measuring the hydroxylation-coupled stoichiometric release of 14 C-labeled CO 2 from 2-oxo[1-14 C]glutarate in a reaction volume of 0.250 ml (ref. 18) . Equal amounts of freshly purified wild-type and mutant enzyme were used as catalysts. The K m and V max values for the mutant enzymes relative to wild-type enzyme for a synthetic peptide DLDLEMPAYIPMDDDFQL (DLD19) and HIF-2αODDD produced and purified in Escherichia coli 41 were determined by varying the concentration of the substrate while keeping the concentrations of the cosubstrates constant. The K m and V max values for oxygen were determined by varying the oxygen concentration in a hypoxia workstation (InVivo 2 400, Ruskinn Technology) and keeping the concentration of the substrate (HIF-2αODDD) and those of the other cosubstrates constant. The K m values for 2-oxoglutarate were determined under normoxia by varying the concentration of 2-oxoglutarate while keeping those of the substrate (DLD19) and the other cosubstrates constant. Statistical analyses comparing the K m and V max values for each mutant PHD2 with the values for wild-type enzyme were performed using the Student's two-tailed t test.
EGLN1 shRNA knockdown and rescue assays. EGLN1 cDNA (wild-type and variant) was subcloned into pLenti-Ubcp-Flag-HA-gateway-PGK-HYG expression vector using Gateway technology (Life Technologies), and constructs were confirmed by DNA sequencing. Hep3B cells (American Type Culture Collection; tested negative for mycoplasma) were infected with lentiviruses encoding Venus fluorescent protein or the PHD2 constructs. After selection in 200 µg/ml hygromycin, cells were infected with lentivirus expressing control shRNA or EGLN1 shRNA (TRCN0000001042, Broad Institute TRC shRNA library) and were selected in 2 µg/ml puromycin. Cells were maintained in DMEM containing 10% FBS, 200 µg/ml hygromycin, 2 µg/ml puromycin and 1% penicillin-streptomycin in the presence of 21% O 2 and 5%
